Related Experiment Video
Updated: Feb 11, 2026

A Doxorubicin-Induced Murine Model of Dilated Cardiomyopathy In Vivo
Published on: May 16, 2020
Dilated cardiomyopathy myosin mutants have reduced force-generating capacity
Zoltan Ujfalusi1,2, Carlos D Vera3, Srbolujub M Mijailovich4
1From the School of Biosciences, University of Kent, Canterbury CT2 7NJ, United Kingdom.
Insights
Dilated cardiomyopathy (DCM) mutations in cardiac myosin impair heart muscle force generation. These mutations reduce myosin
Area of Science:
- Cardiovascular Biology
- Molecular Muscle Physiology
- Biochemistry
Background:
- Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) are serious heart conditions.
- Cardiac myosin mutations are a known cause of these cardiomyopathies.
- Understanding myosin's motor domain function is crucial for disease mechanisms.
Purpose of the Study:
- To functionally characterize the motor domains of five DCM-causing mutations in human β-cardiac myosin.
- To elucidate the specific kinetic alterations in the ATPase cycle caused by DCM mutations.
- To compare the functional effects of DCM mutations with previously studied HCM mutations.
Main Methods:
- Kinetic analyses of individual ATPase cycle steps.
- Measurement of rate constants for ATP binding, hydrolysis, and ADP release.
- Determination of altered affinities for ATP, ADP, and actin.
- Modeling of the complete ATPase contraction cycle.
Main Results:
- Each DCM mutation altered distinct steps in the myosin ATPase cycle.
- Four DCM mutations reduced the myosin duty ratio by decreasing force-holding complex occupancy.
- DCM mutations blunted the load-induced increase in ADP release rate.
- DCM mutants showed more economical ATP utilization compared to wild-type and HCM mutants.
Conclusions:
- DCM-causing myosin mutations lead to impaired force generation and holding capacity.
- Deficits in the force-holding state underlie the functional impairment in DCM.
- The kinetic alterations caused by DCM mutations differ from those in HCM, despite similar phenotypes.
Abstract:
Dilated cardiomyopathy (DCM) and hypertrophic cardiomyopathy (HCM) can cause arrhythmias, heart failure, and cardiac death. Here, we functionally characterized the motor domains of five DCM-causing mutations in human β-cardiac myosin. Kinetic analyses of the individual events in the ATPase cycle revealed that each mutation alters different steps in this cycle. For example, different mutations gave enhanced or reduced rate constants of ATP binding, ATP hydrolysis, or ADP release or exhibited altered ATP, ADP, or actin affinity. Local effects dominated, no common pattern accounted for the similar mutant phenotype, and there was no distinct set of changes that distinguished DCM mutations from previously analyzed HCM myosin mutations. That said, using our data to model the complete ATPase contraction cycle revealed additional critical insights. Four of the DCM mutations lowered the duty ratio (the ATPase cycle portion when myosin strongly binds actin) because of reduced occupancy of the force-holding A·M·D complex in the steady state. Under load, the A·M·D state is predicted to increase owing to a reduced rate constant for ADP release, and this effect was blunted for all five DCM mutations. We observed the opposite effects for two HCM mutations, namely R403Q and R453C. Moreover, the analysis predicted more economical use of ATP by the DCM mutants than by WT and the HCM mutants. Our findings indicate that DCM mutants have a deficit in force generation and force-holding capacity due to the reduced occupancy of the force-holding state.
Related Concept Videos
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Lung Capacity
Electromotive Force
Cardiomyopathy V: Interprofessional Care

